Nathan Hill
Pulmonary Disease · Little Rock, ARNPI 1801207857
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Olympus America Inc. at 60.0% of the total. Reporting peaked in 2020 at $5,443 and has fallen 83.8% since, to $882 in 2025.
Across 167 payments — averaging $54.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$5K
- GSK$646
- Boehringer Ingelheim$533
- Olympus Corporation$345
- AstraZeneca$282
- Sanofi$264
- plus $2K from 20 others
What the payments were for
- Consulting fees$4,31348%
- Travel & lodging$1,44016%
- Food & beverage$3,31937%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 10 | $5,443 |
| GSK | 45 | $646 |
| Boehringer Ingelheim | 27 | $533 |
| Olympus Corporation | 5 | $345 |
| AstraZeneca | 15 | $282 |
| Sanofi | 9 | $264 |
| Mallinckrodt Hospital Products Inc. | 7 | $193 |
| Grifols USA, LLC | 8 | $189 |
| Stryker | 1 | $184 |
| Mylan Specialty L.p. | 7 | $164 |
| Intuitive Surgical | 1 | $134 |
| Vifor Pharma, Inc. | 5 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $91 |
| Verona Pharma, Inc. | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Electromed, Inc. | 3 | $58 |
| Actelion Pharmaceuticals US, Inc. | 2 | $51 |
| Viatris Specialty LLC | 2 | $48 |
| Merck | 2 | $44 |
| Baxter Healthcare | 2 | $43 |
| Pinnacle Biologics, Inc | 2 | $41 |
| Johnson & Johnson | 2 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $21 |
| Inogen, Inc. | 1 | $15 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,072 in reported general payments places this provider in the 75th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 43 | $559,399 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 354 | $247,834 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $34,576 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $25,337 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $20,383 |
| Spiriva RespimatTiotropium Bromide | 28 | $16,219 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $15,911 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $14,904 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 161 | $5,180 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $4,466 |
| Ventolin HfaAlbuterol Sulfate | 25 | $1,551 |
| Montelukast Sodium | 138 | $815 |
| Methylprednisolone | 76 | $462 |
| Azithromycin | 61 | $392 |
| Prednisone | 40 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $533 | $600,954108 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $646 | $298,320455 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $282 | $35,28863 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
- Nancy RectorLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.